Specialty Pharmacy

An interaction with passionate pharmacist and co-worker caused E. Ashley Gulyas, PharmD, to enroll in pharmacy school after nearly a decade of work as a pharmacy technician.

Evobrutinib is an oral inhibitor of Bruton’s tyrosine kinase in development for several autoimmune diseases.

Experimental drug elicits response in diverse population of patients with cancer.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

There was no statistically significant difference in medication possession ratio among HIV-positive patients taking generic or branded antiretrovirals.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Administrative costs and surgical procedures may contribute significantly to overspending on health care in the United States.

Eliminating dormant HIV reserves that hide from antiretroviral therapy is key to curing the virus.

Patients with multiple sclerosis may be at a higher risk of developing mental health conditions.

Certain amino acids may be key to delivering effective, low-dose gene therapy for neurologic conditions.

Top news of the day from across the health care landscape.

Enrollment and dosing in IGNITE DMD has been indefinitely discontinued.

Occupational exposure to oncology medications and other hazardous drugs has been a mounting public health concern for several decades. Health care workers may be exposed to hazardous drugs while preparing, administering, or disposing of drugs or while handling bodily fluids of treated patients.

Kyle Truitt, Co-Founder, Turning Point, LLC, speaks about how pharmaceutical manufacturers can benefit from the launch of the High-Performing Specialty Pharmacy Association.

Collecting data that show the most efficient and effective ways to clinically manage patients is becoming more important than ever in specialty pharmacy.

Gene-editing technology may be more effective reducing cardiovascular risks than targeting PCSK9.

A newer drug may preserve quality of life better than chemotherapy for patients with renal cell carcinoma.

Top news of the day from across the health care landscape.

The Approved Drug Products with Therapeutic Equivalence Evaluations is commonly known as the Orange Book.

Officials with the FDA have approved Medtronic’s continuous glucose monitoring (CGM) system (Guardian Connect) for use by individuals living with diabetes, according to a company press release.

Payers may achieve an additional discount for alirocumab (Praluent) if they agree to value-based contracts.

A gene mutation linked to chordoid gliomas may result in targeted treatment options.

Findings suggest that incomplete transcription causes latency in HIV infected cells.

Top news of the day from across the health care landscape.

Olaparib (Lynparza) double objective response rate compared with other breast cancer drugs.

Targeted administration of chemotherapy and immunotherapy may improve treatment of low-immunogenic tumors.

Ron Lanton III, Esq., President, True North Political Solutions, speaks about proposed legislation that could bolster the emergence of biosimilars.

Intake of fish high in omega-3 fatty acids could help reduce the risk of developing multiple sclerosis or clinically isolated syndrome.

A strain of Staphylococcus epidermidis may be able to reduce skin cancer growth.